Search
Search titles only
By:
Search titles only
By:
Menu
Forums
New posts
Search forums
Home
What's new
New posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
Menu
Install the app
Install
Reply to thread
Home
Heath
Alternative Medicine
Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
[QUOTE="greenmedinfo, post: 2621"] PMID: Drug Deliv. 2021 Dec ;28(1):2534-2547. PMID: 34854788 Abstract Title: Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis. Abstract: Liver fibrosis is a major global health concern. Management of chronic liver disease is severely restricted in clinics due to ineffective treatment approaches. However, a lack of targeted therapy may aggravate this condition. Asiatic acid (AA), a pentacyclic triterpenoid acid, can effectively protect the liver from hepatic disorders. However, the pharmaceutical application of AA is limited by low oral bioavailability and poor targeting efficiency. This study synthesized a novel liver-targeting material from PEG-SA, chemically linked to ursodeoxycholic acid (UA), and utilized it to modify AA nanostructured lipid carriers (UP-AA-NLC) with enhanced targeting and improved efficacy. The formulation of UP-AA-NLC was optimized via the Box-Behnken Experimental Design (BBD) and characterized by size, zeta potential, TEM, DSC, and XRD. Furthermore,antifibrotic activity and proliferation of AA and NLCs were assessed in LX-2 cells. The addition of UP-AA-NLC significantly stimulated the TGF-beta1-induced expression ofα-SMA, FN1, and Col I α1.near-infrared fluorescence imaging and distribution trials in rats demonstrated that UP-AA-NLC could significantly improve oral absorption and liver-targeting efficiency. Oral UP-AA-NLC greatly alleviated carbon tetrachloride-induced liver injury and fibrosis in rats in a dosage-dependent manner, as reflected by serum biochemical parameters (AST, ALT, and ALB), histopathological features (H&E and Masson staining), and antioxidant activity parameters (SOD and MDA). Also, treatment with UP-AA-NLC lowered liver hydroxyproline levels, demonstrating a reduction of collagen accumulation in the fibrotic liver. Collectively, optimized UP-AA-NLC has potential application prospects in liver-targeted therapy and holds great promise as a drug delivery system for treating liver diseases. [URL='https://www.greenmedinfo.com/article/liver-targeted-delivery-asiatic-acid-nanostructured-lipid-carrier-treatment-li']read more[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Home
Heath
Alternative Medicine
Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis.
Top
Bottom
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…